

Daily Program Schedule

Wednesday, September 27

P In Person
 D On-Demand
 V Virtual

| | | | |
|---------------|--|--|-------------|
| 08:00 - 08:30 | PRESIDENT'S ADDRESS P V D | Nikhil Munshi | Trianti |
| 08:30 - 09:00 | KEYNOTE P D Somatic mutations in normal tissues | Peter Campbell | Trianti |
| 09:00 - 14:30 | EXHIBITION OPEN | | Muses Foyer |
| 09:00 - 09:15 | EXHIBITION AND COFFEE BREAK | | Muses Foyer |
| 09:15 - 11:15 | ORIGIN OF MM CELLS P V D <i>Chair: Nikhil Munshi, Co-Chair: Faith Davies</i> Charting the genetic evolution in myeloma cell Novel in vivo models of myeloma origin Failure of immune surveillance and disease evolution Is there a role for screening in monoclonal gammopathies? OA-17: Tracking the earliest genomic events in multiple myeloma life-history OA-33: Aberrant B cell differentiation induce plasma cell malignancy OA-25: MM B cells and pre-plasma cell progenitors are the cellular origin of MM disease relapse following effective therapy targeting plasma cells Discuss abstracts in context Round Table discussion | Faith Davies Karin Vanderkerken Madhav Dhodapkar Sigurdur Kristinsson Anthony Cirrincione Wen Zhou Rodger Tiedemann Leif Bergsagel Rafael Fonseca, Andrew Spencer, Rodger Tiedemann, Marta Chesi | Trianti |
| 11:15 - 11:30 | EXHIBITION AND COFFEE BREAK | | Muses Foyer |

11:30 - 13:00

**INDUSTRY SYMPOSIUM SUPPORTED
BY BRISTOL MYERS SQUIBB** **P** **V** **D**

Trianti

Harnessing the Immune System Before and After CAR T Cell Therapies

| | |
|---|-----------------|
| Welcome and Introduction | Hermann Einsele |
| Update on CAR T cell therapy development | Hermann Einsele |
| Managing CAR T cell therapies in the real world | Yi Lin |
| Immune Profiling and Cellular Therapies | Bruno Paiva |
| Immune-Based Strategies for Improving Outcomes | Rakesh Popat |
| Audience Q&A | Rakesh Popat |

13:00 - 14:30

EXHIBITION AND LUNCH

Muses Foyer and Courtyard

13:30 - 14:30

POSTER SESSION 1 **P**

Trianti Upper Foyer

14:30 - 16:30

**NEWLY DIAGNOSED
MULTIPLE MYELOMA** **P** **V** **D**

Trianti

Chair: Maria-Victoria Mateos, Co-Chair: Vincent Rajkumar

What is the optimal upfront therapy - 3 or 4 drugs? Saad Usmani

Who needs an autologous stem cell transplant upfront? Aurore Perrot

What is the ideal duration of treatment: MRD-guided or until progression? Kwee Yong

Optimizing supportive care management Evangelos Terpos

OA-10: Four years treatment with Zoledronic Acid is superior to two years in protection against progressive bone disease in Multiple Myeloma Thomas Lund

OA-43: Analysis of sustained MRD-negativity and Progression-free Survival of Isa-KRd in High-Risk Newly Diagnosed Multiple Myeloma – Additional Data from Planned Interim Analysis of the GMMG-CONCEPT Trial Lisa Leypoldt

OA-14: Persistent bone marrow and imaging MRD negativity may guide the duration of lenalidomide maintenance following ASCT in patients with multiple myeloma Panagiotis Malandrakis

Discuss abstracts in context and unmet needs Vincent Rajkumar

Round Table discussion Michele Cavo, Sergio Giralt, Thierry Facon, Jean-Luc Harousseau, Vania Hungria, Bindu Kanapuru

16:30 - 16:45

COFFEE BREAK

Muses Foyer

16:45 - 17:45

**ABSTRACT SESSION 1:
MRD AND RISK STRATIFICATION** **P** **D**

Skalkotas

Co-Chairs: Morie Gertz and Hartmut Goldschmidt

OA-12: Predictors of unsustained measurable residual disease (MRD) negativity in transplant-eligible multiple myeloma (MM) patients
Camila Guerrero

OA-37: Optimization of the 20/2/20 risk stratification model for patients with smoldering multiple myeloma through integration of the evolving patterns of monoclonal protein and serum free light chains
Annika Werly

OA-31: Efficacy of Bispecific Antibodies in the Treatment of Extramedullary disease and High risk cytogenetics in Relapsed Multiple Myeloma: A Systematic Review
Charan Vegivinti

OA-38: Physical activity interventions to improve functional performance in patients with multiple myeloma
Jens Hillengass

OA-49: Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from the CC-92480-MM-002 trial
Albert Oriol

16:45 - 17:45

ABSTRACT SESSION 2: BIOLOGY **P** **D**

Mitropoulas

Co-Chairs: Annemeik Broji and Lugui Qiu

OA-35: High-throughput plasma proteomics to define the precursor multiple myeloma proteome and identify candidate high-risk disease biomarkers of progression
Elizabeth Lightbody

OA-21: Dysregulated APOBEC3B promotes cell proliferation and DNA damage in multiple myeloma
Afsaneh Panahi

OA-36: sBCMA predicts progression and is a biomarker of response in myeloma precursor disease followed on prospective studies
wei tan

OA-15: Serial MRD Assessments as a Surrogate for Long Term Progression Free Survival
Frits van Rhee

OA-30: Critical roles of CRIP1 in promoting cell survival and bortezomib resistance by enhancing proteasome activity and autophagy in multiple myeloma
Hao Mu

17:45 - 18:30

FIRESIDE CHAT **P** **D**

Trianti

Siddhartha Mukherjee/Sagar Lonial/Vincent Rajkumar

18:30 - 19:45

EXHIBITION OPEN

Muses Foyer

18:30 - 19:45

WELCOME TO ATHENS RECEPTION

Muses Foyer and Courtyard

Thursday, September 28

| | | |
|---------------|---|--|
| 07:00 - 08:00 | MEET THE PROFESSOR P | |
| MR1 | Understanding the concept of MGRS | Nelson Leung |
| MR2 | Optimal imaging approaches in MM | Elena Zamagni and Jens Hillengass |
| MC2 | Management of bone disease | Andrew Yee and Ramon García Sanz |
| MC3 | Light Chain Amyloidosis | Anita D'Souza and Ashutosh Wechalekar |
| MC3.2 | Racial disparity: impact and solutions | Lalit Kumar and Craig Cole |
| MC3.3 | Clonal hematopoiesis in myeloma: Implications for therapy | Enrique Ocio and Adam Sperling |
| MC3.4 | Managing Renal Failure in MM | Efstathios Kastritis and Pankaj Malhorta |
| 07:00 - 08:00 | CAREER DEVELOPMENT WORKSHOP P | |
| Skalkotas | Nuts and bolts of developing a clinical trial | Marc Raab and Charlotte Pawlyn |
| 08:00 - 09:00 | EHA-IMS SYMPOSIUM P D | Trianti |
| | <i>Co-Chairs: Pieter Sonnevled and Nikhil Munshi</i> | |
| | MRD and CLL | Paolo Ghia |
| | AML and MRD | Jacqueline Cloos |
| | Regulatory Perspective on MRD in hematological malignancies | Nicole Gormley |
| 09:00 - 10:00 | IMS AWARDS P V D | Trianti |
| 10:00 - 13:30 | EXHIBITION OPEN | Muses Foyer |
| 10:00 - 10:15 | EXHIBITION AND COFFEE BREAK | Muses Foyer |

10:15 - 12:15

NOVEL TECHNOLOGY AND INSIGHTS OF MM **P** **V** **D**

Trianti

Chair: Kenneth Anderson, Co-Chair: Gareth Morgan

| | |
|--|--|
| Single cell approach to defining mechanisms of progression for SMM to MM | Irene Ghobrial |
| Metabolomic alterations defining disease progression in myeloma | Mala Shanmugam |
| Epigenetic drivers of disease progression | Felipe Prosper |
| Defining the myeloma cell proteome | Arun Wiita |
| OA-04: Single cell multi-omic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma | Maximilian Merz |
| OA-01: Exploiting microbiota commensals to potentiate immunotherapy and delay multiple myeloma evolution | Laura Lucia Cogrossi |
| OA-22: TiMMing: Developing an Innovative Suite of Bioinformatic Tools to Harmonize and Track the Origin of Copy Number Alterations in the Evolutionary History of Multiple Myeloma | Andrea Poletti |
| Discuss abstracts in context | Gareth Morgan |
| Round Table discussion | Sonja Zweegman, Herve Avet-Loiseau, Wilson Gonsalves, Jill Corre |

12:15 - 13:30

EXHIBITION AND LUNCH

Muses Foyer and Courtyard

12:30 - 13:30

POSTER SESSION 2 **P**

Trianti Upper Foyer

13:30 - 15:00

INDUSTRY SYMPOSIUM SUPPORTED BY JANSSEN **P** **V** **D**

Trianti

A new frontier? Redirecting treatment strategies in MM

Chair: Michel Delforge

| | |
|--|-----------------|
| Time to combine? Evolving treatment options in NDMM | Leo Rasche |
| Time to tailor? Treatment selection at first relapse and beyond | Michel Delforge |
| Time for T? Expanding treatment paradigms in the later-line RR setting | Roberto Mina |
| Panel discussion and meeting close | |

15:00 - 17:00

TRIPLE CLASS REFRACTORY MYELOMA **P** **V** **D**

Trianti

Chair: Philippe Moreau, Co-Chair: Sagar Lonial

| | |
|---|--|
| How should we define refractoriness in myeloma? | Nizar Bahlis |
| Molecular determinants of drug resistance | Lawrence Boise |
| Role of tumor microenvironment in drug resistance | Suzanne Lentzsch |
| Non-Immune therapy for TCR | Paula Rodriguez-Otero |
| OA-06: Robust in vivo expansion and long-term persistence of anti-BCMA CAR T cells, PHE885, manufactured in < 2 days on the T-Charge platform | Shuntaro Ikegawa |
| OA-23: Resolving therapy resistance mechanisms in multiple myeloma by multi-omics subclone analysis | Alexandra Poos |
| OA-24: Sequential and persistent loss of BCMA and GPRC5D after bispecific antibodies in multiple myeloma revealed by whole genome sequencing | Leo Rasche |
| Discuss abstracts in context | Sagar Lonial |
| Round Table discussion | Ajai Chari, P. Joy Ho, Keith Stewart, Meletios Dimopoulos, Donna Reece, Bindu Kanapuru |

17:00 - 17:15

COFFEE BREAK

Muses Foyer

17:15 - 18:15

ABSTRACT SESSION 3: NOVEL COMBINATIONS, ACCESS AND LONG TERM OUTCOMES **P** **D**

Skalkotas

Co-Chairs: Gordon Cook and Eirini Katodritou

| | |
|---|------------------|
| OA-41: Iberdomide, bortezomib, and dexamethasone (IberVd) in transplant-ineligible newly diagnosed multiple myeloma (NDMM): results from the CC-220-MM-001 trial | Darrell White |
| OA-29: First Results From the Randomized Portion of a Phase 2 Study of Venetoclax Plus Carfilzomib-Dexamethasone vs Carfilzomib-Dexamethasone in Patients With t(11;14) Relapsed/Refractory Multiple Myeloma | Jonathan Kaufman |
| OA-44: Pomalidomide, bortezomib, and dexamethasone vs bortezomib and dexamethasone in relapsed or refractory multiple myeloma (OPTIMISMM): final survival outcomes from a randomized, open-label, phase 3 trial | Meral Beksac |
| OA-42: Second Primary Malignancies after Tandem Autologous Hematopoietic Stem Cell Transplantation for patients with Multiple Myeloma Treated on Earlier Total Therapy Protocols | Samer Al Hadidi |
| OA-54: Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone with tandem transplant in high-risk newly diagnosed myeloma patients: final results of the phase 2 study IFM 2018-04 | Cyrille Touzeau |

17:15 - 18:15

ABSTRACT SESSION 4: GENOMICS **P** **D**

Mitropoulos

Co-Chairs: Mark Bustoros and Masood Shammas

OA-19: Comprehensive genomic characterization of response and resistance to daratumumab- based quadruplet induction in newly diagnosed multiple myeloma patients
Kylee Maclachlan

OA-16: The rs9344 G risk allele upregulates CCND1 expression through t(11;14) and PAX5 in multiple myeloma
Linda Baughn

OA-46: Epigenetic regulation of CD38/48 by KDM6A mediates NK cell response in multiple myeloma
Jiye Liu

OA-28: Unraveling the heterogeneity of multiple myeloma associated with therapy resistance by single-cell RNA sequencing
Takahiro Kamiya

OA-18: Identification of therapy-induced clonal evolution and resistance pathways in MRD clones in multiple myeloma through single-cell sequencing
Jian Cui

19:00 - 22:00

IMS CULTURAL CELEBRATION

Ble Azure

Friday, September 29

07:00 - 08:00

MEET THE PROFESSOR **P**

MR1 Approaches to MRD assessment
Ajay Nooka and Suzanne Trudel

MR2 Waldenström Macroglobulinemia
Prashant Kapoor and Veronica Leblond

MC2 Assessing QOL and PRO measures
Tanya Wilde and Raphael Szalat

MC3 Laboratory assessment of immune function
David Avigan and Heinz Ludwig

MC3.2 Single cell genomic techniques for study of myeloma
Samir Parekh and Brian Walker

MC3.3 Proteomic evaluation in MM
Constantine Mitsiades and Manoj Bhasin

MC3.4 Optimizing in vitro cellular models of MM
Mariateresa Fulciniti and Niccolo Bolli

07:00 - 08:00

CAREER DEVELOPMENT WORKSHOP **P**

Skalkotas

Setting up your laboratory research program
Paola Neri and Mehmet Samur

| | | |
|---------------|---|--|
| 08:00 - 09:00 | RINEY SESSION P D <i>Co-Chairs: Kenneth Anderson and Nikhil Munshi</i> | Trianti |
| | Liquid biopsy in myeloma to inform outcome and treatment decisions | Jens Lohr |
| | Molecular characterization and therapeutic targeting of protein kinase D2 in T(414) multiple myeloma | Raphael Szalat |
| | PNC-27: A Novel Effective Strategy for Targeting the Achilles' Heel of Multiple Myeloma | Flavia Pichiorri |
| | Deciphering the human plasma cell niche and its transformation in multiple myeloma by highly multiplexed tissue imaging | Marc-A. Baertsch |
| 09:00 - 09:30 | YOUNG INVESTIGATOR AWARDS P | Trianti |
| 09:30 - 14:15 | EXHIBITION OPEN | Muses Foyer |
| 09:30 - 09:45 | EXHIBITION AND COFFEE BREAK | Muses Foyer |
| 09:45 - 11:45 | PRACTICAL ASPECTS P V D OF IMMUNOTHERAPY <i>Chair: Jesus San Miguel, Co-Chair: Noopur Rajee</i> | Trianti |
| | Integrating T cell redirection in frontline MM | Adam Cohen |
| | How do we sequence CART, Bispecifics and ADC and other drugs? | Niels van de Donk |
| | Managing acute Immunotherapy complications | Krina Patel |
| | Prevention and monitoring of infections with immunotherapies | Joshua Richter |
| | OA-07: Phase I Study of BCMA CAR-T Using Instant Manufacturing Platform or Traditional Production Process for Relapsed/Refractory Multiple Myeloma Therapy | Hui Liu |
| | OA-11: Utility of 18FDG-PET/CT for Risk Prediction in Relapsed/Refractory Multiple Myeloma Patients Undergoing CAR-T Cell Therapy: Analysis of Baseline and Early Assessment Scans After One and Three Months | Luis-Esteban Tamariz-Amador |
| | OA-51: Preliminary Recommendations for Prevention and Management of Infections, Hypogammaglobulinemia, and Neutropenia During Treatment With Teclistamab Based on Experience From the MajesTEC-1 Study | Niels van de Donk |
| | Discuss abstracts in context | Noopur Rajee |
| | Round Table discussion | Jesus Berdaja, Ivan Borrello, Monika Engelhardt, Sham Mailankody, Tom Martin |

Current Issues in Multiple Myeloma: Management of the Aging Population*Chair: Paul Richardson*

Increasing heterogeneity of the aging MM patient population: diagnostic challenges

Alessandra Larocca

Aging of the general population and its impact on MM treatment

Yael Cohen

Treatment options for elderly patients in early RRMM: Immunomodulatory agents, proteasome inhibitors, and anti-CD38 antibodies

Paul Richardson

BCMA-targeted treatment options for elderly patients in early RRMM

Hang Quach

Roundtable discussion: Practical considerations: eligibility, access and benefit/risk

All speakers

Audience Q&A

Closing remarks

12:45 - 14:15

EXHIBITION AND LUNCH

Muses Foyer and Courtyard

13:15 - 14:15

POSTER SESSION 3 **P**

Trianti Upper Foyer

14:15 - 16:15

PLENARY SESSION **P** **V** **D**

Trianti

Co-Chairs: Bob Orłowski and Qing Yi

OA-20: Genomic profiling of high-risk smoldering myeloma patients treated with a curative strategy: a biological study of the phase II GEM CESAR clinical trial.

Alejandro Medina-Herrera

Summarize Abstract

Samir Parekh

OA-27: Single cell transcriptomics reveals the impact of tumor cell interactions with the bone marrow immune microenvironment in the progression of multiple myeloma

Parvathi Sudha

Summarize Abstract

Paola Neri

OA-45: Pharmacokinetic and correlative analysis of ciltacabtagene autoleucl in patients with lenalidomide-refractory multiple myeloma in the CARTITUDE-4 trial

Carlos Fernandez de Larrea

Summarize Abstract

Tom Martin

OA-48: Isatuximab plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma (IKEMA): Final Overall Survival Analysis

Philippe Moreau

Summarize Abstract

Sagar Lonial

OA-52: Results From the Randomized, Open-Label Phase 3 CANOVA Study of Venetoclax Versus Pomalidomide Added to Dexamethasone in Patients With t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

Maria-Victoria Mateos

Summarize Abstract

Faith Davies

| | |
|--|------------------|
| OA-53: Peripheral Blood and Bone Marrow Residual Disease Negativity to Identify a Subgroup of Newly Diagnosed Multiple Myeloma Patients with Long Term Disease Control | Noemi Puig |
| Summarize Abstract | Kenneth Anderson |

16:15 - 16:30 **COFFEE BREAK** Muses Foyer

16:30 - 17:30 **ABSTRACT SESSION 5: IMMUNE THERAPIES** **P** **D** Skalkotas

Co-Chairs: Simon Harrison and Katja Weisel

| | |
|---|----------------|
| OA-05: Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): analysis of patient- and disease-related factors associated with responses | Simon Harrison |
|---|----------------|

| | |
|--|---------------|
| OA-55: Real world experience of patients treated with teclistamab: a BCMA-directed bispecific t-cell engaging therapy for multiple myeloma | Shonali Midha |
|--|---------------|

| | |
|--|----------------|
| OA-47: Additional analysis of CARTITUDE-4: Cilta-cel vs standard of care (Pvd or DPd) in lenalidomide-refractory patients with multiple myeloma and 1-3 prior lines of therapy | Salomon Manier |
|--|----------------|

| | |
|--|------------|
| OA-08: GPRC5D-Targeted CAR-T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma Progressing after or Refractory to BCMA CAR-T cell therapy: Updated Results from a Phase 2 Clinical Trial | Jieyun Xia |
|--|------------|

| | |
|--|------------|
| OA-34: Feasibility of a novel academic anti-BCMA chimeric antigen receptor T-cell (CART) (HBI0101) for the treatment of relapsed and refractory AL amyloidosis | Eyal Lebel |
|--|------------|

16:30 - 17:30 **ABSTRACT SESSION 6: IMMUNE** **P** **D** Mitropoulas

Co-Chairs: Eileen Boyle and Fanghuang Zhan

| | |
|---|--------------|
| OA-32: The Impact of Genomics to Identify Novel Immunotherapeutic Targets in Multiple Myeloma | Brian Walker |
|---|--------------|

| | |
|--|-------------------------|
| OA-02: α -NKG2A blockade overcomes multiple myeloma resistance to BCMA and NKG2D CAR-NKAE cells | Jessica Encinas Mayoral |
|--|-------------------------|

| | |
|--|-------------------|
| OA-09: Combination of forimtamig with standard of care improves depth and duration of response in preclinical models of multiple myeloma | Aintzane Zabaleta |
|--|-------------------|

| | |
|---|----------|
| OA-26: Single-cell analysis reveals disease induced perturbations of monocytes in the bone marrow and peripheral blood of multiple myeloma patients | Jian Cui |
|---|----------|

| | |
|---|----------------|
| OA-03: Bispecific T-cell engager response is driven by pre-treatment CD8+ effector memory cells and inhibited by TIGIT+ Tregs in relapsed/refractory multiple myeloma | Ross Firestone |
|---|----------------|

Saturday, September 30

| | | |
|---------------|--|---|
| 08:00 - 09:00 | MEET THE PROFESSOR P | |
| MR1 | Risk stratified follow up of MGUS and SMM | Meral Beksac and Natalie Callander |
| MR2 | Vaccination and infection prevention | Kartik Ramasamy and Dorotea Fantl |
| MC2 | Solitary tumor plasmacytoma | Carlos Fernandez de Larrea and Andrzej Jakubowiak |
| MC3 | Diagnostic approach to a monoclonal protein (lab-based) | Dave Murray and Joan Bladé |
| MC3.2 | Neuropathy and MGUS | Jorge Castillo and Andrew Branagan |
| MC3.3 | Castleman's and POEMS | Angela Dispenzieri and Frits van Rhee |
| MC3.4 | Artificial Intelligence in Myeloma: what would its utility be? | Marta Sonia González and Claudio Cerchione |
| 08:00 - 09:00 | CAREER DEVELOPMENT WORKSHOP P | |
| Skalkotas | The art of writing grants | Jens Lohr and Mattia D'Agostino |
| 09:00 - 09:40 | SPECIAL SESSION P D | Trianti |
| | <i>Co-Chairs: Meletios Dimopoulos and Efstathios Kastritis</i> | |
| | Waldenström Macroglobulinemia | Steven Treon |
| | Amyloidosis | Vaishali Sanchorawala |
| 09:40 - 10:00 | COFFEE BREAK | Muses Foyer |
| 10:00 - 11:00 | INDUSTRY SYMPOSIUM SUPPORTED BY SANOFI P V D | Trianti |
| | Monoclonal Antibody based therapies | |
| | <i>Chair: Joseph Mikhael</i> | |
| | Welcome and intro: Importance of an individualised approach to achieve the best outcomes | Joseph Mikhael |
| | Individualizing frontline treatment to get the best outcomes | Xavier Leleu |
| | Patient cases - RRMM | Elizabeth O'Donnell |
| | Personalizing treatment approaches beyond frontline | Fredrik Schjesvold |
| | Audience Q&A | |
| 11:00 - 11:15 | COFFEE BREAK | Muses Foyer |

11:15 - 13:15

CHALLENGES IN MM P V D

Trianti

Chair: Shaji Kumar, Co-Chair: Francesca Gay

| | |
|--|---|
| Defining high-risk and ultra-high risk MM | Martin Kaiser |
| Molecular drivers of extramedullary progression | Moritz Binder |
| Management of EMD and plasma cell leukemia | Laura Rosiñol |
| Managing the older, frail patient with multiple co-morbidities | Salomon Manier |
| OA-13: Increased levels of circulating tumor cells correlate with adverse clinical outcomes and distinct biological features in newly diagnosed patients with multiple myeloma | Ioannis Kostopoulos |
| OA-40: Frailty and initial treatment intensity in patients newly diagnosed with multiple myeloma | Clark DuMontier |
| OA-39: Development and Validation of a Prognostic Survival Model with Patient Reported Outcomes for Older Adults with Multiple Myeloma | Hira Mian |
| Discuss abstracts in context | Francesca Gay |
| Round Table discussion | Wee Joo Chng, Cristina Gasparetto, Sundar Jagannath, Hira Mian, Mohamad Mohty |

13:15 - 13:30

CLOSING CEREMONY P D

Trianti

13:45 - 14:45

SPECIAL CAREER DEVELOPMENT SESSION P D

Skalkotas

Panelists: Suzanne Lentzsch, Andrew Branagan, Ravi Vij

The IMS gratefully acknowledges the following organizations for their sponsorship of the 20th IMS Annual Meeting:

TITANIUM LEVEL



PLATINUM LEVEL



GOLD LEVEL



BRONZE LEVEL

